Allan Carr odds is 1 in 3. If one considered sepsis prevention/cure nothing new besides antibiotics has worked. Then one have the failures: 1.Synergen, 2 Bayer, 3 Lipo, 4 Cnto, 5 ABTI, 6 Xoma's E5.
Of the six, only xoma's E5 and maybe Cnto (same approach) had some value but both were rejected by FDA and both are dormant. E5 still could resurface in combination with Bpi down the road. So, this is now 0 out of 6, so the odds are higher against sepsis drugs, flip the same coin and one could say the next one has the bullet: BPI is the one (plus all the great basic science behind it, and the good PIIs behind it) this is the one.
Antiinflamatory work in sepsis (xoma's goal) has been very elusive, maybe some of the genome approach will bring something (far) maybe the rexinoid/retinoids research will bring some help (far), and the only one in PIII besides BPI that I know of is Acetyl hydrolase to block PAF (platelet activation factor) that together with TNF (tumor necorsis factor) and feeding each other viciously are able to bring the worse activation of the inflamatory cascade leading to shock. The approach to block TNF failed (synergen, bayer) in sepsis, but it work against Rheumatoid Arthritis (Inmunex success) and Amgn is behind same type of work. Xoma is still the big hope against sepsis. The Acetyl hidrolase approach is probably good, but they are trying it in a very complex sepsis related disease of premature babies (Necrotizing Enterocolitis) a very focus approach (and very strange to be investigated first in this population) , I like their basic science,(I do not remember if is LaJolla, or some other pharma behind it). But if AH works it could be synergistic with BPI, and many of the others could also be.
George, cacaito is little cocoa (the fruit name in spanish is cacao), but when my friends are upset they use the other meaning, and if they are badly upset they use a g (cagaito).
With similar sentimental feelings,
cacaito |
